TAK Zasocitinib: FDA Priority Review for Psoriasis

Takeda (TAK) said the FDA accepted its new drug application for zasocitinib (TAK-279) under Priority Review for adults with moderate-to-severe plaque psoriasis, with a target action date in the first quarter of 2027 (company release). Zasocitinib is a once-daily oral TYK2 inhibitor that would compete directly against Bristol Myers Squibb’s Sotyktu, the first TYK2 drug approved for psoriasis in 2022.

The filing rests on the Phase 3 LATITUDE program, studies 3001 and 3002, which met co-primary endpoints and all 44 ranked secondary endpoints across nearly 3,000 patients. Takeda reports the drug was generally well tolerated with no new safety signals. The European Medicines Agency has also accepted a marketing application.

TYK2, tyrosine kinase 2, is an enzyme in the JAK family that sits upstream of IL-23 and other immune pathways that drive psoriasis. Zasocitinib is engineered for more than a million-fold selectivity for TYK2 over JAK1, JAK2, and JAK3, which Takeda argues maximizes skin clearance while sparing the JAK pathways tied to the class’s boxed-warning side effects. Sotyktu (deucravacitinib) is also a TYK2 inhibitor but binds a different regulatory site, so the two drugs will be differentiated on dosing and efficacy rather than on being first to the mechanism. Because zasocitinib spares JAK1, JAK2, and JAK3, Takeda is positioning it to avoid the boxed warnings that have kept many JAK inhibitors as later-line options, while an oral once-daily pill gives patients an alternative to injectable biologics.

The commercial question is whether an oral pill can take share in a psoriasis market still dominated by injectable biologics. Plaque psoriasis affects roughly 8 million people in the U.S. and over 100 million worldwide, and oral options were a gap in the treatment picture until Sotyktu arrived. Priority Review signals the FDA believes the drug would offer a meaningful improvement over existing options. Sotyktu has reached roughly $291 million in annual sales, leaving room for a second oral TYK2 entrant. Another oral contender, J&J’s icotrokinra, is advancing through the same field, as covered in the oral IL-23 psoriasis piece.

TAK closed September 25 at $18.86, a $60 billion market cap for a company with roughly $30 billion in annual revenue. Takeda is also running zasocitinib through Phase 3 in psoriatic arthritis and Phase 2 in Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa, which would turn a single approval into a broader immunology franchise. What to watch next: the exact PDUFA date and the psoriatic arthritis readout, which will determine whether zasocitinib becomes a franchise or a single-indication drug.

What It Means for the Trade

The trade is a Q1 2027 PDUFA on a drug with 44-for-44 ranked secondary endpoints across nearly 3,000 patients — that is about as clean a Phase 3 program as immunology delivers, and Priority Review means the FDA agrees the drug matters. The commercial question is not approval odds but share capture. Sotyktu has plateaued around $291 million a year, which reads two ways: the oral TYK2 category is proven but not yet huge, and a second entrant with differentiated chemistry has room to grow the category rather than split it. Takeda’s $60 billion market cap means psoriasis alone moves nothing — the leverage is the label ladder: psoriatic arthritis Phase 3, plus Crohn’s, ulcerative colitis, vitiligo, and hidradenitis suppurativa behind it. A psoriasis approval turns zasocitinib into a launch platform for a broader immunology franchise, which is where a $30 billion-revenue company actually feels it. Watch the psoriatic arthritis readout as the franchise-or-single-indication decision point.

Mechanism and Market Context

TYK2 sits upstream of IL-23 and the other immune pathways that drive psoriasis, and zasocitinib’s pitch is precision: more than a million-fold selectivity for TYK2 over JAK1, JAK2, and JAK3. That selectivity is the whole commercial argument, because it is what keeps the drug positioned to avoid the boxed warnings that have held oral JAK inhibitors to later-line use. Sotyktu binds a different regulatory site on the same enzyme, so the two will compete on dosing, efficacy depth, and safety perception rather than on first-to-mechanism. The prize is the injectable-biologic share: roughly 8 million US patients and over 100 million worldwide, with orals a persistent gap in the treatment picture.

Risks and What Could Go Wrong

1. The boxed-warning question is not settled until the final label — regulators decide positioning, not Takeda’s argument.
2. Sotyktu has a four-year commercial head start and first-mover formulary positioning.
3. J&J’s icotrokinra is advancing through the same oral lane and could out-efficacy both TYK2s.
4. Without a psoriatic arthritis win, zasocitinib stays a single-indication product in a category whose leader earns under $300 million a year.